Gilead and Glympse Bio announce strategic collaboration for use of biomarker technology in NASH clinical development

This article was originally published here

“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases,

The post Gilead and Glympse Bio announce strategic collaboration for use of biomarker technology in NASH clinical development appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply